A Phase 1, Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) in First Relapse.

Trial Profile

A Phase 1, Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) in First Relapse.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2015

At a glance

  • Drugs Clofarabine (Primary) ; Cyclophosphamide; Etoposide; Pegaspargase; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 17 May 2011 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Planned end date changed from 1 Aug 2012 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top